---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-26-000044"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-08-05T20:02:41+00:00"
generated_at: "2026-08-05T20:04:44.554487+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mirum Q2 net product sales $176M, raises FY guidance to $680-700M; volixibat NDA delayed to H1 2027

## Summary
- Q2 2026 net product sales $176.2M, up 38% YoY; LIVMARLI sales $128.7M (+46% YoY), Bile Acid Medicines $47.5M (+20% YoY).
- Full-year 2026 net product sales guidance raised to $680-700M from prior range.
- Volixibat granted Breakthrough Therapy and Orphan Drug Designations for PSC; pre-NDA meeting recommended Phase 3 study, NDA submission now targeted H1 2027.
- Issued $690M of 0.00% convertible senior notes due 2032; settled $237.2M of 4.00% notes due 2029.
- Cash and investments $561.3M as of June 30, 2026; zilurgisertib PDUFA date Sept 26, 2026.

## SEC filing metadata
- accession: 0001759425-26-000044
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-08-05T20:02:41+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/0001759425-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-26-000044
- JSON: https://secwatch.observer/filing/0001759425-26-000044.json
- Plain text: https://secwatch.observer/filing/0001759425-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.